Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
Soo Yeon BaekWoo Chul NohSei-Hyun AhnHyun-Ah KimJai Min RyuSeung Il KimEun Gyeong LeeSeock-Ah ImYong Sik JungMin Ho ParkKyong Hwa ParkSu Hwan KangJoon JeongEun Hwa ParkSung Yong KimMin Hyuk LeeLee Su KimWoosung LimSeon Ok KimHee Jeong KimPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Adding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy.